Association of clinical trial enrollment and survival using contemporary therapy for pediatric acute lymphoblastic leukemia
Clinical trial enrollment did not affect pediatric B‑ALL survival.
We investigated the association between enrollment on contemporary trials and event‑free survival (EFS) in pediatric B‑cell acute lymphoblastic leukemia (B‑ALL). In a retrospective cohort of 274 children (1‑21 years) treated for B‑ALL from 2008 to 2015, 55.5 % enrolled with no disparity in enrollment by age, sex, or ethnicity. Three‑year EFS was similar for enrolled and not enrolled patients (90.1 % vs 86.5 %). Clinical trial enrollment did not affect pediatric B‑ALL survival.
The results suggest that trial participation does not improve survival in the modern minimal residual disease‑based treatment era.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia